Published Paper Details:

The CRISPR-associated protein 9 (Cas9) system is primarily a defensive mechanism utilized by bacteria to protect themselves from phage invasion. Endometrial cancer, a particular type of gynecological cancer, poses a serious hazard to people all over the world because to the high occurrence of the PTEN gene mutation. It has, however, been purposely exploited as a powerful foundation for RNA-guided DNA targeting, making genome editing, transcriptional disruption, epigenetic alteration, and genome imaging more manageable. When using a fusion protein of nuclease-deficient Cas9 and effector domain, this technology allows for precise manipulation of any genomic sequence specified by a short stretch of guide RNA, allowing for the elucidation of gene function involved in disease development and progression, correction of disease-causing mutations, active therapeutic approaches include rectifying disease-causing mutations, inactivating oncogenes, and activating deactivated cancer suppressor genes. The CRISPR-Cas9 in-silico operation was performed using the ChopChop technique version 3. CHOPCHOP is suitable for a variety of CRISPR applications, including gene knock-out, sequence knock-in, and RNA knock-down. Using CHOPCHOP's visualization, gRNAs may be chosen through knowledge and experimentation. CHOPCHOP v3 broadens the variety of DNA targeting methods available. Among these are (i) mechanisms for nanopore enrichment. Targeted sequencing is the process of obtaining high-quality sequencing reads in a specified area of interest. CHOPCHOP v3 is limited to sgRNA searches inside each isoform, which necessitates knocking off the PTEN gene with IDT Technology. The gRNA had to be selected for usage since "Molecular Scissor" is a procedure that uses primer design to assist the UCSC Genome Browser in measuring the variation of the intron and exon variation in the targeted gene by target sequences. Furthermore, this programmable endonuclease technique allows scientists to investigate the roles of multiple gene sequences concurrently by targeting multiple genomic loci in a single experiment, greatly accelerating our understanding of pathological processes involving large sets of genes or mutations, such as tumor development. CRISPR-based genome-wide screens using single-guide RNA (Sg RNA) libraries can be used to identify drug-target or disease-resistance genes, such as novel tumor suppressors or oncogenes, as well as to rapidly assess therapeutic targets. Drug-target or disease-resistance genes, such as novel tumor suppressors or oncogenes, can also be exploited to quickly identify therapeutic targets. The CRISPER-CAS9 gene editing technique, as a novel therapeutic impact method, emphasizes the need of understanding the mechanism of endometrial cancer therapy. CRISPRs, or clustered regularly interspaced short palindromic repeats, were developed as a gene editing tool. CRISPR-associated (CAS) nucleases, which are guided by single guide RNAs (sgRNAs), can be used to fix mutations in disease-associated genes and delete specific genes. When it comes to creating genetic alterations or mutations, the CRISPR/Cas9 system outperforms earlier methods.